Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 56

1.

Clonal Relatedness and Mutational Differences between Upper Tract and Bladder Urothelial Carcinoma.

Audenet F, Isharwal S, Cha EK, Donoghue MTA, Drill EN, Ostrovnaya I, Pietzak EJ, Sfakianos JP, Bagrodia A, Murugan P, Dalbagni G, Donahue TF, Rosenberg JE, Bajorin DF, Arcila ME, Hechtman JF, Berger MF, Taylor BS, Al-Ahmadie H, Iyer G, Bochner BH, Coleman JA, Solit DB.

Clin Cancer Res. 2019 Feb 1;25(3):967-976. doi: 10.1158/1078-0432.CCR-18-2039. Epub 2018 Oct 23.

PMID:
30352907
2.

Cystectomy for benign disease: readmission, morbidity, and complications.

Erpelding SG, Dugan A, Isharwal S, Strup S, James A, Gupta S.

Can J Urol. 2018 Oct;25(5):9473-9479.

PMID:
30281004
3.

The 17-Gene Genomic Prostate Score Assay Predicts Outcome After Radical Prostatectomy Independent of PTEN Status.

Magi-Galluzzi C, Isharwal S, Falzarano SM, Tsiatis A, Dee A, Maddala T, Knezevic D, Febbo PG, Lawrence J, Klein EA.

Urology. 2018 Nov;121:132-138. doi: 10.1016/j.urology.2018.07.018. Epub 2018 Aug 22.

4.

Acute Kidney Injury after Partial Nephrectomy of Solitary Kidneys: Impact on Long-Term Stability of Renal Function.

Zabell J, Isharwal S, Dong W, Abraham J, Wu J, Suk-Ouichai C, Palacios DA, Remer E, Li J, Campbell SC.

J Urol. 2018 Dec;200(6):1295-1301. doi: 10.1016/j.juro.2018.07.042. Epub 2018 Jul 20.

PMID:
30036515
5.

Current Therapeutic Strategies in Clinical Urology.

Crane A, Isharwal S, Zhu H.

Mol Pharm. 2018 Aug 6;15(8):3010-3019. doi: 10.1021/acs.molpharmaceut.8b00383. Epub 2018 Jun 28.

PMID:
29924627
6.

Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.

Isharwal S, Huang H, Nanjangud G, Audenet F, Chen YB, Gopalan A, Fine SW, Tickoo SK, Lee BH, Iyer G, Chadalavada K, Rosenberg JE, Bajorin DF, Herr HW, Donat SM, Dalbagni G, Bochner BH, Solit DB, Reuter VE, Al-Ahmadie HA.

Hum Pathol. 2018 Jul;77:63-69. doi: 10.1016/j.humpath.2018.03.015. Epub 2018 Mar 27.

PMID:
29601842
7.

Tumor Contact Surface Area As a Predictor of Functional Outcomes After Standard Partial Nephrectomy: Utility and Limitations.

Suk-Ouichai C, Wu J, Dong W, Tanaka H, Wang Y, Zhang JJH, Caraballo E, Remer E, Li J, Isharwal S, Campbell SC.

Urology. 2018 Jun;116:106-113. doi: 10.1016/j.urology.2018.02.030. Epub 2018 Mar 6.

PMID:
29522868
8.

Kidney, Ureteral, and Bladder Cancer: A Primer for the Internist.

Arora HC, Fascelli M, Zhang JH, Isharwal S, Campbell SC.

Med Clin North Am. 2018 Mar;102(2):231-249. doi: 10.1016/j.mcna.2017.10.002. Review.

PMID:
29406055
9.

Impact of Comorbidities on Functional Recovery from Partial Nephrectomy.

Isharwal S, Ye W, Wang A, Abraham J, Zabell J, Dong W, Wu J, Suk-Ouichai C, Caraballo ER, Gao T, Campbell SC.

J Urol. 2018 Jun;199(6):1433-1439. doi: 10.1016/j.juro.2017.12.004. Epub 2017 Dec 7.

PMID:
29225058
10.

Post-prostatectomy radiation therapy for locally recurrent prostate cancer.

Isharwal S, Stephenson AJ.

Expert Rev Anticancer Ther. 2017 Nov;17(11):1003-1012. doi: 10.1080/14737140.2017.1378575. Epub 2017 Sep 18. Review.

PMID:
28922958
11.

Predictors of Long-Term Survival after Renal Cancer Surgery.

Zabell J, Demirjian S, Lane BR, Derweesh IH, Isharwal S, Suk-Ouichai C, Wu J, Palacios DA, Campbell SC.

J Urol. 2018 Feb;199(2):384-392. doi: 10.1016/j.juro.2017.08.096. Epub 2017 Aug 30.

PMID:
28859893
12.

Prognostic Value of TERT Alterations, Mutational and Copy Number Alterations Burden in Urothelial Carcinoma.

Isharwal S, Audenet F, Drill E, Pietzak EJ, Iyer G, Ostrovnaya I, Cha E, Donahue T, Arcila M, Jayakumaran G, Berger MF, Rosenberg JE, Bajorin DF, Coleman J, Dalbagni G, Reuter VE, Bochner BH, Solit DB, Al-Ahmadie HA.

Eur Urol Focus. 2017 Aug 10. pii: S2405-4569(17)30189-X. doi: 10.1016/j.euf.2017.07.004. [Epub ahead of print]

13.

Ischemia and Functional Recovery from Partial Nephrectomy: Refined Perspectives.

Dong W, Wu J, Suk-Ouichai C, Caraballo Antonio E, Remer EM, Li J, Zabell J, Isharwal S, Campbell SC.

Eur Urol Focus. 2018 Jul;4(4):572-578. doi: 10.1016/j.euf.2017.02.001. Epub 2017 Mar 3.

PMID:
28753855
14.

Functional Comparison of Renal Tumor Enucleation Versus Standard Partial Nephrectomy.

Dong W, Gupta GN, Blackwell RH, Wu J, Suk-Ouichai C, Shah A, Capodice SE, Quek ML, Caraballo Antonio E, Aguilar Palacios D, Remer EM, Li J, Zabell J, Isharwal S, Campbell SC.

Eur Urol Focus. 2017 Oct;3(4-5):437-443. doi: 10.1016/j.euf.2017.06.002. Epub 2017 Jun 16.

PMID:
28753814
15.

Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.

Pietzak EJ, Bagrodia A, Cha EK, Drill EN, Iyer G, Isharwal S, Ostrovnaya I, Baez P, Li Q, Berger MF, Zehir A, Schultz N, Rosenberg JE, Bajorin DF, Dalbagni G, Al-Ahmadie H, Solit DB, Bochner BH.

Eur Urol. 2017 Dec;72(6):952-959. doi: 10.1016/j.eururo.2017.05.032. Epub 2017 Jun 3.

16.

Devascularized Parenchymal Mass Associated with Partial Nephrectomy: Predictive Factors and Impact on Functional Recovery.

Dong W, Wu J, Suk-Ouichai C, Caraballo Antonio E, Remer E, Li J, Zabell J, Isharwal S, Campbell SC.

J Urol. 2017 Oct;198(4):787-794. doi: 10.1016/j.juro.2017.04.020. Epub 2017 Apr 9.

PMID:
28400188
17.

Minnelide Inhibits Androgen Dependent, Castration Resistant Prostate Cancer Growth by Decreasing Expression of Androgen Receptor Full Length and Splice Variants.

Isharwal S, Modi S, Arora N, Uhlrich C 3rd, Giri B, Barlass U, Soubra A, Chugh R, Dehm SM, Dudeja V, Saluja A, Banerjee S, Konety B.

Prostate. 2017 May;77(6):584-596. doi: 10.1002/pros.23298. Epub 2017 Feb 1.

PMID:
28144973
18.

Excised Parenchymal Mass During Partial Nephrectomy: Functional Implications.

Dong W, Zhang Z, Zhao J, Wu J, Suk-Ouichai C, Aguilar Palacios D, Caraballo Antonio E, Babbar S, Remer EM, Li J, Isharwal S, Zabell J, Campbell SC.

Urology. 2017 May;103:129-135. doi: 10.1016/j.urology.2016.12.021. Epub 2016 Dec 21.

PMID:
28011276
19.

Does endorectal coil MRI increase the accuracy of preoperative prostate cancer staging?

Pooli A, Isharwal S, Cook G, Oliveto JM, LaGrange CA.

Can J Urol. 2016 Dec;23(6):8564-8567.

PMID:
27995852
20.

Clinical Correlates of Benefit From Radium-223 Therapy in Metastatic Castration Resistant Prostate Cancer.

Alva A, Nordquist L, Daignault S, George S, Ramos J, Albany C, Isharwal S, McDonald M, Campbell G, Danchaivijitr P, Yentz S, Anand A, Yu EY.

Prostate. 2017 Apr;77(5):479-488. doi: 10.1002/pros.23286. Epub 2016 Dec 19.

21.

Urinalysis findings are not predictive of positive urine culture in patients with indwelling stents.

Pooli A, Cook G, Isharwal S, Desai V, LaGrange C.

Can J Urol. 2016 Oct;23(5):8446-8450.

PMID:
27705729
22.

Preoperative frailty predicts postoperative complications and mortality in urology patients.

Isharwal S, Johanning JM, Dwyer JG, Schimid KK, LaGrange CA.

World J Urol. 2017 Jan;35(1):21-26. doi: 10.1007/s00345-016-1845-z. Epub 2016 May 12.

PMID:
27172940
23.

Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials.

Kaushik D, Vashistha V, Isharwal S, Sediqe SA, Lin MF.

Ther Adv Urol. 2015 Dec;7(6):388-95. doi: 10.1177/1756287215597637. Review.

24.

Patient-Provider Communication About Prostate Cancer Screening and Treatment: New Evidence From the Health Information National Trends Survey.

Bhuyan SS, Chandak A, Gupta N, Isharwal S, LaGrange C, Mahmood A, Gentry D.

Am J Mens Health. 2017 Jan;11(1):134-146. doi: 10.1177/1557988315614082. Epub 2016 Jul 7.

25.

Non-muscle invasive bladder cancer risk stratification.

Isharwal S, Konety B.

Indian J Urol. 2015 Oct-Dec;31(4):289-96. doi: 10.4103/0970-1591.166445. Review.

26.

Evaluation of two mitochondrial DNA biomarkers for prostate cancer detection.

Maragh S, Veltri RW, Lund SP, Mangold L, Isharwal S, Christudass CS, Partin AW, Humphreys EB, Sorbara L, Srivastava S, Wagner PD.

Cancer Biomark. 2015;15(6):763-73. doi: 10.3233/CBM-150518.

PMID:
26406418
27.

Penile cancer in a man with netherton syndrome.

Isharwal S, Manivel JC, Konety B.

Urology. 2015 Apr;85(4):e21-2. doi: 10.1016/j.urology.2014.12.042.

PMID:
25817126
28.

Desmoid tumor: an unusual case of gross hematuria.

Isharwal S, Desai V, Horn A, Lele SM, Lagrange CA.

Ther Adv Urol. 2015 Feb;7(1):49-51. doi: 10.1177/1756287214553969.

29.

Chronic lymphocytic leukemia of the bladder: an atypical etiology of gross hematuria.

Desai V, Isharwal S, Pooli A, Lele S, Feloney M.

Ther Adv Urol. 2014 Oct;6(5):198-200. doi: 10.1177/1756287214535461. Review.

30.

Management of clinical stage I nonseminomatous germ cell tumors.

Isharwal S, Risk MC.

Expert Rev Anticancer Ther. 2014 Sep;14(9):1021-32. doi: 10.1586/14737140.2014.928593. Epub 2014 Jun 14. Review.

PMID:
24931909
31.

The N-terminal domain of the androgen receptor drives its nuclear localization in castration-resistant prostate cancer cells.

Dar JA, Masoodi KZ, Eisermann K, Isharwal S, Ai J, Pascal LE, Nelson JB, Wang Z.

J Steroid Biochem Mol Biol. 2014 Sep;143:473-80. doi: 10.1016/j.jsbmb.2014.03.004. Epub 2014 Mar 22.

32.

Concomitant loss of EAF2/U19 and Pten synergistically promotes prostate carcinogenesis in the mouse model.

Ai J, Pascal LE, O'Malley KJ, Dar JA, Isharwal S, Qiao Z, Ren B, Rigatti LH, Dhir R, Xiao W, Nelson JB, Wang Z.

Oncogene. 2014 May 1;33(18):2286-94. doi: 10.1038/onc.2013.190. Epub 2013 May 27.

33.

Hypermethylation of genes detected in urine from Ghanaian adults with bladder pathology associated with Schistosoma haematobium infection.

Zhong X, Isharwal S, Naples JM, Shiff C, Veltri RW, Shao C, Bosompem KM, Sidransky D, Hoque MO.

PLoS One. 2013;8(3):e59089. doi: 10.1371/journal.pone.0059089. Epub 2013 Mar 18.

34.

Association of [-2]proPSA with biopsy reclassification during active surveillance for prostate cancer.

Tosoian JJ, Loeb S, Feng Z, Isharwal S, Landis P, Elliot DJ, Veltri R, Epstein JI, Partin AW, Carter HB, Trock B, Sokoll LJ.

J Urol. 2012 Oct;188(4):1131-6. doi: 10.1016/j.juro.2012.06.009. Epub 2012 Aug 15.

35.

Secondary vaginoplasty for disorders for sexual differentiation: is there a right time? Challenges with compliance and follow-up at a multidisciplinary center.

Willihnganz-Lawson KH, Isharwal S, Lewis JM, Sarafoglou K, Boisclair-Fahey A, Shukla AR.

J Pediatr Urol. 2013 Oct;9(5):627-32. doi: 10.1016/j.jpurol.2012.06.015. Epub 2012 Aug 9.

PMID:
22884689
36.

Nuclear morphometry, nucleomics and prostate cancer progression.

Veltri RW, Christudass CS, Isharwal S.

Asian J Androl. 2012 May;14(3):375-84. doi: 10.1038/aja.2011.148. Epub 2012 Apr 16. Review.

37.

Regenerated luminal epithelial cells are derived from preexisting luminal epithelial cells in adult mouse prostate.

Liu J, Pascal LE, Isharwal S, Metzger D, Ramos Garcia R, Pilch J, Kasper S, Williams K, Basse PH, Nelson JB, Chambon P, Wang Z.

Mol Endocrinol. 2011 Nov;25(11):1849-57. doi: 10.1210/me.2011-1081. Epub 2011 Sep 22.

38.

ProPSA and diagnostic biopsy tissue DNA content combination improves accuracy to predict need for prostate cancer treatment among men enrolled in an active surveillance program.

Isharwal S, Makarov DV, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW.

Urology. 2011 Mar;77(3):763.e1-6. doi: 10.1016/j.urology.2010.07.526. Epub 2011 Jan 8.

39.

Prediction of patient-specific risk and percentile cohort risk of pathological stage outcome using continuous prostate-specific antigen measurement, clinical stage and biopsy Gleason score.

Huang Y, Isharwal S, Haese A, Chun FK, Makarov DV, Feng Z, Han M, Humphreys E, Epstein JI, Partin AW, Veltri RW.

BJU Int. 2011 May;107(10):1562-9. doi: 10.1111/j.1464-410X.2010.09692.x. Epub 2010 Sep 28. Erratum in: BJU Int. 2011 Oct;108(7):1232.

40.

Nuclear roundness variance predicts prostate cancer progression, metastasis, and death: A prospective evaluation with up to 25 years of follow-up after radical prostatectomy.

Veltri RW, Isharwal S, Miller MC, Epstein JI, Partin AW.

Prostate. 2010 Sep 1;70(12):1333-9. doi: 10.1002/pros.21168.

PMID:
20623633
41.

Pro-prostate-specific antigen measurements in serum and tissue are associated with treatment necessity among men enrolled in expectant management for prostate cancer.

Makarov DV, Isharwal S, Sokoll LJ, Landis P, Marlow C, Epstein JI, Partin AW, Carter HB, Veltri RW.

Clin Cancer Res. 2009 Dec 1;15(23):7316-21. doi: 10.1158/1078-0432.CCR-09-1263. Epub 2009 Nov 24.

42.

Non-invasive methods to detect schistosome-based bladder cancer: is the association sufficient for epidemiological use?

Shiff C, Naples JM, Isharwal S, Bosompem KM, Veltri RW.

Trans R Soc Trop Med Hyg. 2010 Jan;104(1):3-5. doi: 10.1016/j.trstmh.2009.05.013. Epub 2009 Aug 21. Review.

PMID:
19699502
43.

DNA content in the diagnostic biopsy for benign-adjacent and cancer-tissue areas predicts the need for treatment in men with T1c prostate cancer undergoing surveillance in an expectant management programme.

Isharwal S, Makarov DV, Carter HB, Epstein JI, Partin AW, Landis P, Marlow C, Veltri RW.

BJU Int. 2010 Feb;105(3):329-33. doi: 10.1111/j.1464-410X.2009.08791.x. Epub 2009 Aug 12.

44.

Diet & insulin resistance: a review & Asian Indian perspective.

Isharwal S, Misra A, Wasir JS, Nigam P.

Indian J Med Res. 2009 May;129(5):485-99. Review.

PMID:
19675375
45.
46.

Valproic acid causes dose- and time-dependent changes in nuclear structure in prostate cancer cells in vitro and in vivo.

Kortenhorst MS, Isharwal S, van Diest PJ, Chowdhury WH, Marlow C, Carducci MA, Rodriguez R, Veltri RW.

Mol Cancer Ther. 2009 Apr;8(4):802-8. doi: 10.1158/1535-7163.MCT-08-1076.

47.

DNA Ploidy as surrogate for biopsy gleason score for preoperative organ versus nonorgan-confined prostate cancer prediction.

Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW, Veltri RW.

Urology. 2009 May;73(5):1092-7. doi: 10.1016/j.urology.2008.09.060. Epub 2009 Feb 3.

48.

Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.

Hu R, Dunn TA, Wei S, Isharwal S, Veltri RW, Humphreys E, Han M, Partin AW, Vessella RL, Isaacs WB, Bova GS, Luo J.

Cancer Res. 2009 Jan 1;69(1):16-22. doi: 10.1158/0008-5472.CAN-08-2764.

49.

South Asian diets and insulin resistance.

Misra A, Khurana L, Isharwal S, Bhardwaj S.

Br J Nutr. 2009 Feb;101(4):465-73. doi: 10.1017/S0007114508073649. Epub 2008 Oct 9. Review.

PMID:
18842159
50.

Prognostic value of Her-2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy.

Isharwal S, Miller MC, Epstein JI, Mangold LA, Humphreys E, Partin AW, Veltri RW.

Int J Cancer. 2008 Dec 1;123(11):2636-43. doi: 10.1002/ijc.23838.

Supplemental Content

Loading ...
Support Center